# Agni-01 (NCT06060613)

> Safety and Efficacy of OBX-115 in Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06060613
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Obsidian Therapeutics, Inc.
- Conditions: Tumor Skin; Metastatic Melanoma; Melanoma; Lung Cancer; Metastatic Lung Cancer; Non Small Cell Lung Cancer; Metastatic Non Small Cell Lung Cancer
- Interventions: OBX-115
- Enrollment: 254
- Primary outcome: Incidence and nature of dose-limiting toxicities (DLTs)
- Primary outcome: The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1
- Primary outcome: The proportion of participants who have a confirmed complete response (CR) or partial response (PR) per RECIST v1.1

## Commentary we found

- YouTube: 8
- Podcasts: 6
- X threads: 3

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=agni-01-nct06060613

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06060613", "email": "<work email>"}; the inbox owner confirms by the emailed link.